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Abstract 
Douglas Reed, PhD 
Roles of Antibody in Vaccine-Elicited Protection Against Virulent Francisella tularensis 
Aerosolized Infection 
Emily L. Olsen, MS 
University of Pittsburgh, 2020 
Abstract 
Francisella tularensis, the causative agent of tularemia, is a facultative intracellular 
bacterium that infects a wide variety of cell types, most notably phagocytes. Initial studies of F. 
tularensis focused on using plasma to passively immunize subjects as a mechanism of protection, 
with varied results. Here, we purified the antibodies from plasma of rabbits that were immunized 
in a prime-boost schedule of a live attenuated mutant of virulent Ft. tularensis (Schu S4 ΔAroD) 
infection that also survived challenge from the fully virulent strain. We also examined the ability 
of the antibodies to opsonize and fix complement to Ft. holarctica Live Vaccine Strain. When 
BALB/c mice were passively immunized either intraperitoneally or intranasally with our 
polyclonal antibody solutions there was an extension of time to death in lethal doses, significantly 
less weight loss in immunized animals, and a slight decrease in bacterial titers within the tissues 
of animals. These data indicate that while antibodies alone are not a mechanism of protection in 
the mouse model, they do reduce clinical disease and may play a role in vaccine-mediated 
protection against aerosolized infection with the Live Vaccine Strain. These findings further 
warrant future studies in other animal models that recapitulate human disease. These findings 
contribute to the development of therapeutics for infection, and are significant to public health 
because of the potential of F. tularensis to be used as a biological weapon.
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1.0 Introduction 
Francisella tularensis, the causative agent of tularemia, is a gram-negative coccobacillus 
that establishes infection extracellularly and intracellularly in a wide range of cells. It was 
originally discovered in 1911 by George McCoy while investigating an outbreak of what was 
believed to be plague in ground squirrels (1) in Tulare County, California, subsequently naming 
the agent Bacterium tularense. Two years later, Edward Francis determined that the outbreak of 
“deer fly fever” in the Midwest and later the common “rabbit fever” butchers developed from 
processing infectious rabbits were both caused by the same organism, naming the condition 
tularemia. The name of bacterium was later changed to Francisella tularensis in his honor (1). 
There are currently four subspecies of F. tularensis: tularensis (type A), holarctica (type B), 
novicida, and mediasiatica. Of these, subspecies tularensis is the most virulent and is primarily 
found in the United States. Type B is more common than type A and primarily seen in both the 
United States and Europe. All subspecies are almost exclusively seen in the Northern Hemisphere 
(2). Subspecies mediasiatica and novicida are not known to cause disease in humans who are 
immunocompetent. 
Currently, there is no vaccine licensed for use in the United States, although there is an 
attenuated strain “Live Vaccine Strain” (LVS) that is used as investigational new drug to some at-
risk personnel (3). This strain was originally developed from a Ft holarctica strain by the USSR 
and was attenuated through serial passage before being gifted to the United States. The exact 
mechanisms of attenuation in humans are unknown, leading to concerns of spontaneous reversion. 
In this study, we use the Rocky Mountain Labs (RML) LVS strain. This strain is reported to be 
more virulent than the commercial LVS biovar (ATCC LVS) (4). 
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1.1 Francisella tularensis Disease and Epidemiology 
1.1.1 Routes of Infection, Clinical Disease, Epidemiology 
The symptoms and severity of infections with F. tularensis vary by subspecies and route 
of entry (5). The most common natural source of infection is through tick bites and contact with 
infected animals such as mice, deer, or rabbits. This often produces the ulceroglandular or 
glandular form of disease, which is characterized by an ulcer forming at the site of infection as 
well as lymphadenopathy, malaise, fever, chills, and other signs of generalized febrile illness. The 
glandular form of disease lacks an ulcer but is otherwise comparable. If the bacteria are present in 
contaminated food, the resulting disease, the oropharyngeal form, often portrays as ulcers along 
the mucus membranes as well as tonsillitis, pharyngitis, stomatitis, as well as lymphadenopathy 
(2). Rarely, infection can also occur in the eye, oculoglandular, which is characterized by 
conjunctivitis, ulcers, and lymphadenopathy. Septic infections are systemic and do not have 
localized swelling of lymph nodes – this clinical presentation often occurs in conjunction with 
other symptoms. Inhalation of the bacteria results in one of the more severe forms of disease, 
pneumonic tularemia. It has been reported that as few as 10 CFUs of bacteria (6) are capable of 
causing this type of infection. In this form of disease, the febrile illness symptoms occur, as well 
as coughing and chest pain. If left untreated, the mortality is approximately 40% of all cases of 
pneumonic tularemia. All forms of tularemia can cause lasting symptoms for weeks and require 
an antibiotic regime for 10-21 days (7).  
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1.1.1.1 Focus on Aerosol Infections 
In the Reed Lab, the primary focus is infections of the respiratory tract and aerosol 
inoculation. Inhalation of F. tularensis by small particle aerosol has been shown by the Reed Lab 
and others to have an extremely low infectious dose and results in a serious disease depending on 
model organism and bacterial strain (8). In addition to its low infectious dose, Francisella species 
are relatively stable when aerosolized either naturally or manually in the lab setting and are 
relatively simple to produce in mass quantities. These characteristics of this bacteria as well as its 
history have led the Center for Disease Control (CDC) to classify it as a Tier 1 Select Agent, which 
are biological specimens that have the highest capability/likelihood of being weaponized (9). In 
1969, the U.S. renounced their offensive biological weapons program, which included research 
into weaponizing Francisella species. In 1972, the U.S. and several other countries signed a treaty 
at the Biological Warfare Convention agreeing to cease production of biological weapons. 
However, the U.S.S.R., a signee of the treaty, continued to produce bioweapons, including 
Francisella (10). In addition, F. tularensis has caused outbreaks when aerosolized naturally, such 
as during the periodic “lawnmower tularemia” cases seen in Martha’s Vineyard (11). These cases 
were caused when rabbit dens were unintentionally run over by lawnmowers during routine 
maintenance, aerosolizing the bacteria. 
1.1.2 Epidemiology of Natural Francisella Infection 
Francisella species are endemic almost exclusively to the Northern Hemisphere, as shown 
in Figure 1 (12). Subspecies tularensis, the most virulent subspecies, is found primarily in the 
U.S. Ft. holarctica is more widespread and is found in Europe and across Asia as well as North 
America.  
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Figure 1 Global distribution of all subspecies of F. tularensis. 
 
In the U.S., cases are primarily seen in the Midwest and Central states with some outbreaks 
in other states. Figure 2 is from the CDC’s database showing tularemia cases reported from 2018 
(13). Cases in the U.S. are relatively rare, making this disease difficult to diagnose (7).  
 
Figure 2 U.S. Cases of Tularema in 2018. 
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1.2 Immune Response to Francisella tularensis and Current Vaccine Strategies 
1.2.1 Francisella tularensis Pathogenesis and Host Response 
Unlike other gram negative bacteria such as Escherichia coli, F. tularensis 
lipopolysaccharide capsule does not serve as an endotoxin (14). Instead, it is currently thought that 
the tissue damage and subsequent disease is caused by a large bacterial burden within the tissues 
and blood (15) and is partially mediated by the host response. During infection, F. tularensis has 
the ability to infect many different cell types, including erythrocytes (16), splenocytes , 
hepatocytes, neutrophils, dendritic cells, and macrophages (17). When phagocytes engulf F. 
tularensis bacteria, the immune cells begin to undergo normal development of the phagosome 
microenvironment until the bacteria escape and enter the cytoplasm of the cell (18). While this 
mechanism is not fully elucidated, it is thought that F. tularensis is able to prevent the acidification 
of the phagosome and this in turn allows the bacteria to destabilize the membrane of the phagosome 
(18, 19). Once inside the cytosol of the host cell, F. tularensis begins to produce specific proteins 
required for intracellular growth. Some of these products are known, such as the IglC protein 
required for escape and intracellular growth; but, most are hypothetical proteins with hypothesized 
functions (18, 20).  
Virulent strains of Ft. tularensis are often characterized by a generalized immune 
suppression during early infection (14, 15, 21, 22), allowing the bacteria to reproduce to high titers 
in the host and subsequently contribute to virulence. Following this, infection results in a robust 
immune response involving both IgM (23), IgA and hypercytokinemia (24). A robust immune 
response is seen earlier and is less severe in avirulent strains, such as LVS and F. novicida, which 
is widely thought to contribute to the fact that these strains do not cause severe disease in humans 
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(22). Pneumonic tularemia results in respiratory distress and occasionally bacteremia in rabbits 
and mice (8, 25-27). 
1.2.2 Vaccine Strategies 
Licensure of a vaccine in the U.S. to protect against F. tularensis infection is currently only 
possible using the FDA Animal Rule. This rule states that, in cases where it would be unethical or 
immoral to conduct human trials against a pathogen, animal models may be used instead of phase 
III clinical trials (28). Since outbreaks of F. tularensis are rare, it would be difficult to test the 
efficacy of a vaccine candidate by challenging humans, although it has been done in the past (29, 
30). Another stipulation of the FDA Animal Rule is that the exact mechanisms of protection 
elicited by the vaccine must be characterized. The debated role of antibodies (see Table 1) in 
protection against F. tularensis thus warrants further investigation as indicated by the Animal Rule.  
Vaccination efforts for F. tularensis began in the mid-1900s with killed vaccines produced 
by Lee Foshay (30) who used acetone or phenol to prepare samples. These efforts resulted in a 
reduced incidence of disease among lab workers and comparatively more mild disease presentation 
than those who were unvaccinated. However, killed vaccines have been shown to be largely 
ineffective due to the lack of cellular immune response (4, 31, 32). Later, groups attempted to use 
subunit vaccines with the immunogenic antigens from Francisella’s lipopolysaccharide (LPS) 
outer membrane or the O-antigen sugars attached to LPS (33). 
USSR researchers created an attenuated live vaccine from Ft. holarctica (type B) strain, 
naming it the “Live Vaccine Strain” (LVS).  This strain is used in the U.S. as an investigational 
new drug, but is unlikely to be licensed due to its side-effects and unknown exact method of 
attenuation (32). Recent studies in the Reed lab have examined other live-vaccine candidates that 
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are mutants of the virulent Schu S4 strain: ΔaroD, ΔguaBA, and ΔfipB (34) in the rabbit model. 
The AroD mutant conferred 83% protection and warrants further investigation in its use as a 
vaccine. In these experiments, I used rabbit plasma produced from these hyperimmune animals. 
“Hyperimmune” rabbits are animals that have been exposed to F. tularensis a total of three times. 
Rabbits were exposed to AroD twice in a prime-boost vaccination, then challenged with a high-
dose of Schu S4. Surviving animals (83%) were then used as hyperimmune samples (35). 
Survivors exhibited higher IgG titers and little or no clinical symptoms of infection. 
1.3 Humoral Immunity in F. tularensis Infections 
Antibodies are proteins produced by B cells in the body to fight against many different 
pathogens, including intracellular bacteria such as Francisella species. The fragment antigen 
binding (Fab) portion of these proteins are highly specific to a certain epitope on the targeted 
bacteria. Once bound, the fragment crystallizable (Fc) region of the protein binds to different 
receptors on immune cells that subsequently produce a wide variety of responses (31). These 
responses may include direct killing or agglutination of the bacteria, induction of complement 
proteins that kill the bacteria, or uptake of the pathogen into immune cells such as macrophages 
(31). While these mechanisms are relatively well known across different infections, the exact roles 
antibodies play in Francisella tularensis infections is not.  
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Figure 3. Schematic diagram of IgG. 
 
Table 1 shows a visual summary of different articles that examined the use of Ft antibodies 
in protection. In Stenmark’s and Kirimanjeswara’s work, it was found that antibodies were able to 
reduce bacterial burden in animal models (36, 37). Upon investigation of mechanisms, 
Kirimanjeswara found that the process was not complement-mediated but facilitated by FcγR. This 
finding is important because FcγR are known to mediate phagocytosis, a key event in the life cycle 
of F. tularensis. However, Schwartz’s work (23) indicates that complement is mediated through 
IgM, and this functions in bacterial killing while other studies indicate that complement receptors 
facilitate uptake of bacteria but may not result in phagocytes killing Francisella (38).  This is 
important to note because the receptors involved in phagocytosis may facilitate the intracellular 
route of the bacteria, at least initially during infection (38). Other papers (39) conclude that B cells 
but not antibodies function in protection against bacterial infection. Due to these conflicting 
conclusions, the role of antibody during infection is not yet well understood and thus requires 
investigation. 
As previously mentioned, elucidating the exact roles of antibodies in vaccination and 
protection is paramount to vaccine licensure under the FDA Animal Rule.  Antibodies produced 
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by rabbits vaccinated with mutant strains of Ft. tularensis and Ft. holarctica will bind to multiple 
antigens, both inside and outside the Francisella bacterium (25). In addition, the Reed Lab has 
also found that IgG titers in rabbits vaccinated with Schu S4ΔAroD in a prime-boost schedule had 
a weak correlation with survival from virulent Schu S4 challenge. In immunoproteomic studies of 
F. tularensis, researchers found that multiple exposures to Francisella resulted in an increase in 
antibody titer as well as a broader range of specificity to antigens (40-42). In fact, these studies 
show that initial exposure to F. tularensis resulted in antibodies specific to outer membrane 
antigens, such as LPS or the O-antigen but subsequent exposures produced antibody responses 
against cytoplasmic antigens. Antibodies used in this study likely follow this pattern, since the 
rabbits used to produce the antibodies were exposed to F. tularensis multiple times. While many 
groups have examined effects of plasma or monoclonal antibodies, no one has yet to examine the 
effects of a pure polyclonal antibody cocktail produced from multiple exposures of F. tularensis 
in rabbits. Since pre-challenge IgG titers loosely correlated with survival (35), we thought that 
these antibodies might be playing a role in protection and we could replicate experiments produced 
by other groups using hyperimmune rabbit antibodies. 
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Table 1. Summary of Literature Examining Passive Protection Against F. tularensis. 
First Author Year 
Mouse 
Model(s) 
Used 
Strain 
(vaccinated to 
produce Ab) 
Strain 
(challenged) 
Abs used Exposure Results 
Kirimanjeswara, 
G. S. (36) 
2007 
multiple 
mouse 
strains 
103 CFU LVS (i.n) 
104 CFU LVS 
(i.n) 
250 ul (i.p) 
(mouse sera) 
pre/post 
survival (pre), 
prolonged illness 
(post) 
Savitt, A. G. (43) 2009 
BALB/c, 
CH3HeN 
105 CFU LVS 
(i.d) 
7 x 107 LVS  50 ug in 200 
ul (in-house 
Mabs) 
pre/post 
survival (pre), 
prolonged illness 
(post) 
24 CFU 
SCHUS4 
pre-exposure prolonged illness 
Steiner, D. J. (44) 2018 BALB/c 
< 102 CFU LVS 
(prime), 103 LVS 
(boost) (i.n.) 
24-31 cfu 
SCHUS4 (i.n.) 
250 ul (i.p) 
(mouse sera) 
pre-exposure 
survival when 
AMs depleted 
only 
Drabick, J.J. (45) 1994 C3H/HeN LVS in humans 104 LVS (i.p) 
200 ul (i.p) 
(human sera) 
pre-exposure survival 
Stenmark, S. (37) 2003 
C57BL/10, 
C57BL/10-
Igh-6tm1Cg 
5 x 103 CFU LVS 
in C57BL/10 
6 x 107 CFU 
LVS (i.d.) 
.5 ml (i.p.) 
(mouse sera) 
pre-exposure survival 
1st: 5 x 104 CFU 
LVS (i.d.) 
pre-exposure survival 
2nd: 3 x 108 
CFU LVS (i.d.) 
(5wk later) 
pre-exposure survival 
Fulop, M. (46) 2001 BALB/c 
50 ug LPS (x3) 
(i.p.) 
7.1 x 104 CFU 
LVS 
.4 ml (i.p.) 
(mouse sera) 
pre-exposure survival 
above + 106 CFU 
LVS (i.p.) 
100 CFU 
SchuS4  
.4 ml (i.p.) 
(mouse sera) 
pre-exposure 
no significant 
difference 
Francis, E. and 
Felton, L.D. (47) 
1942 white mice 
Ft in horses, 
sheep, rabbits or 
humans 
Japanese strain 
(LVS) 
1 cc (i.p.) 
(various 
animals) 
at same time or 
right after 
challenge 
prolonged illness 
Pannel, L. and 
Cordle, M. (48) 
1962 
Swiss-
webster 
mice 
1ml sublethal dose 
of Jap strain P. 
tularensis 
.5 ml lethal dose 
of Jap strain P.t. 
(i.p.) 
.5 ml (i.p.) 
(mouse sera)  
mix w/ 
challenge 
survival 
1 ml filtrate from 
103 cells/ml of Jap 
strain P. tul 
.5 ml lethal dose 
of Jap strain P.t. 
(i.p.) 
.5 ml (i.p.) 
(mouse sera)  
mix w/ 
challenge 
prolonged illness 
Allen, W.P. (49) 1962 
Swiss mice, 
A/LN mice 
killed whole cell 
SchuS5 (10 x 107 
cells/ml) .5ml for 
5 days 
SchuS5 
.25 ml (i.p) 
(mouse sera) 
pre-exposure prolonged illness 
Chou, A.Y. (39) 2017 
C57BL/6J 
and C57-
BKO 
101 CFU U112 
(i.d.) 
105 or 106 CFU 
U112 i.p. 
.5 ml serum 
+ 101 CFU 
U112 i.d. 
pre-exposure 
no significant 
difference 
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1.3.1 Passive Immunization and Therapeutics 
Initial studies of F. tularensis focuses heavily on passive immunization and protection using 
plasma from vaccinated subjects (29, 47, 48). Many studies found that plasma injected directly 
into animals protected against infection from LVS but often failed to confer protection against 
virulent Schu S4 challenge (see Table 1). Table 1 only shows immunization studies performed in 
mice since passive immunization experiments in this work were performed in mice. However, 
there is one study in the Fisher rat model that showed successful passive immunization against 
Schu S4 challenge (50). More discussion regarding the use of different models can be found in 
section 1.4.2. In studies examining post-exposure inoculation with plasma, researchers found that 
immune plasma injections enabled mice to survive longer than controls against lethal LVS 
infection (36, 43). While these results may not have shown full protection, the data do support the 
notion that antibodies could potentially be used as a supportive therapy following an exposure to 
F. tularensis.  
The passive immunization experiments performed in this study used two different animal 
models in experimental design: antibodies derived from outbred New Zealand White (NZW) 
rabbits were given to BALB/c mice. More details regarding differences in animal models can be 
found in section 1.4.2, but in brief this method has not yet been performed to examine antibodies 
against F. tularensis.  
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1.4 Working with Francisella tularensis in the Laboratory Setting 
1.4.1 Biosafety 
The more virulent strains of Francisella tularensis are classified as BSL3 pathogens, 
meaning that laboratory work on these agents must be performed in stringent BSL3 labs. Of the 
strains mentioned in this study, Ft tularensis (type A) SCHU S4 and SCHU S4ΔaroD are both 
classified as BSL3 pathogens. Other strains, such as Ft. holarctica ATCC LVS and RML LVS are 
BSL2 pathogens. In studies involving animals infected with the more virulent strains, work must 
be performed in high-containment laboratories. This means that lab workers must wear both 
waterproof gowns or suits and gloves as well as respiratory protection. In addition, workers must 
follow special protocols upon bringing out samples from inside the BSL3 facility into the BSL2 
workspace to ensure any viable pathogen is inactivated. Work in high containment labs 
traditionally evolves more slowly than other labs due to these constraints. 
1.4.2 Animal Models for Francisella Infections 
Development of different animal models to examine infection of F. tularensis is an 
additional requirement that researchers face in accordance with the FDA Animal Rule. Each 
animal model has benefits and downfalls in vaccine development. The Reed lab has worked 
extensively on showing that the rabbit model of infection with F. tularensis recapitulates what is 
seen in humans (8, 25, 34, 35, 51). Most notably, rabbits do not develop a severe illness when 
exposed to LVS, like humans. This is a major benefit of the rabbit model over the mouse model 
since the virulence between LVS and other type B strains and especially type A strains has been 
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shown to be dramatically different. Specifically, mice succumb to infection with LVS while other 
models (rat, monkey, rabbit, human) do not. This allows research using the rabbit as a model to 
translate into human disease and treatments. Rabbits are not common models of infectious 
diseases, creating challenges in logistics and reagent supplies available. For example, it is common 
to have commercially available antibodies produced in rabbits but can be difficult to find 
commercial antibodies against rabbits. Mice are suitable models for disease in preliminary studies 
since they are relatively cheap and work with LVS can be done under BSL2 conditions. This makes 
mice an attractive model for many researchers, resulting in numerous papers using murine models. 
As mentioned earlier, this model for disease may not translate to human disease, directly 
conflicting with the FDA Animal Rule requirements needed to generate a vaccine.  
Other animals have also been used to model tularemia. The non-human primate (NHP) 
model of disease shows similar clinical presentation of infection with different strains of F. 
tularensis as the rabbit model (8, 52). However, NHPs are expensive to obtain and maintain, 
making this an unlikely animal to be used in preliminary studies. Recent research using the rat as 
a model has been promising in relating to the human model more so than the mouse (53). However, 
this animal appears to be resistant to lethal infection of Schu S4 in comparison to the NHP model, 
as indicated by the difference in lethal doses (52, 53). 
1.5 Public Health Significance 
Due to its high infectious capability, ease of aerosolization, and ease of mass production 
(54), Francisella tularensis has been deemed a Tier 1 Select Agent by the CDC and the USDA as 
part of the Federal Select Agent Program. This means that F. tularensis has a high likelihood of 
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being used as biological weapon compared to other pathogens in the Select Agent Program. Thus, 
while naturally-occurring infections have been dramatically lowered in the U.S. since the 1940s to 
about 200 cases/year (55), there is still a prerogative to develop protective measures against this 
disease. Currently, the Live Vaccine Strain (LVS) is the only vaccine available; however, it has 
not been approved by the FDA for regular use. There are other strains of attenuated Francisella 
that are used as candidate vaccinations, some of which have been studied in the Reed Lab (34, 35). 
Diagnostic tests for infection include PCR of blood samples, cultures and antibody titers (56). 
Treatment by several antibiotics such as streptomycin, gentamycin, and fluoroquinolones are 
available and effective (7).  
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2.0 Specific Aims 
The aim of this study was to examine the effects that antibodies have on the intracellular 
bacteria F. tularensis. Many studies claim that immunity to F. tularensis is largely cellular and the 
exact roles of antibodies during infection is not well defined. In previous studies, plasma injected 
into mice prior to challenge has been shown to prevent disease from LVS but results vary when 
animals were challenged with virulent strains. Since the rabbit model produces a more diverse 
antibody repertoire after prime-boost vaccination than is seen in mice, we wanted to determine if 
these antibodies were more effective at controlling infection than previously shown. This would 
show that, contrary to popular belief, antibodies do play a role in the protection against Francisella 
infection.  
2.1 Aim 1: Purify and Characterize Antibodies Produced from Hyperimmmune Rabbit 
Plasma 
(a) Determine the optimal concentration of ammonium sulfate required to precipitate 
out all antibodies from rabbit plasma. 
(b) Examine the antibodies purified from hyperimmune rabbit plasma by purification, 
binding, and concentration. 
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Hypothesis:  
1. The use of caprylic acid in addition to ammonium sulfate will precipitate out 
antibodies from rabbit plasma that are relatively pure, highly concentrated, and have 
strong avidity to Francisella. 
2.2 Aim 2: Examine the Potential Role of Antibodies in Protection Elicited by Vaccination 
(c) Examine the effects of antibodies binding to RML LVS using bacterial titers and 
traditional agglutination and complement fixation tests. 
(d) Infect J774A.1 macrophage-like cells with Francisella coated in antibody to examine 
increases in phagocytosis and intracellular growth. 
(e) Passively immunize BALB/c mice and challenge using aerosolized RML LVS to 
determine if antibodies can protect against death. 
Hypotheses:  
1. Antibodies produced by hyperimmune rabbits bind to RML LVS bacteria, causing an 
increase in phagocytosis in J774A.1 cells. 
2. These antibodies, when administered prior to infection, can protect BALB/c mice 
against lethal aerosol infection of RML LVS. 
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3.0 Materials and Methods 
3.1 Animal Models Used and Biosafety 
All animals used during the experiments were housed in pathogen free isolation caging 
inside the Regional Biocontainment Laboratory (BSL3+). Six-to-ten-week-old female BALB/c 
mice were obtained from Charles River and used in experiments where indicated. Mice were 
allowed to adjust to the new cages for 48 hours before any additional handling. All work using 
Select Agents, such as the SchuS4 isolate of F. tularensis, were manipulated in a BSL 3+ lab. 
3.2 Antibody Purification 
Immune and naïve rabbit plasma were purified through a two-step process using caprylic 
acid and precipitation through ammonium sulfate. In the first step, 10 ml of plasma from either 
immune or naïve rabbits was thawed and spun at 10,000x g at 4°C for 30 minutes. The supernatant 
was filtered through Millex .8 µm filters, then twice the volume of .6M sodium acetate buffer was 
added to the supernatant. For a volume of 10ml of filtered plasma, 820 µl of caprylic acid was 
added, dropwise, while stirring, at room temperature (57). After allowing the solution to stir for 
another 30 minutes at room temp, it was then spun at 4,000x g for 30 min at 4°C and dialyzed in 
PBS overnight with 2-3 buffer changes. 
In the second step, immunoglobulin was precipitated out of the solution using saturated 
ammonium sulfate. Ammonium sulfate was added dropwise to the dialyzed supernatant at 4°C, 
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while stirring, until a final concentration of 43% was reached (58). This solution was spun at 
10,000x g for 30 min at 4°C. The pellet was resuspended in 2ml of PBS for future analysis. In 
addition, all fractions from previous steps were saved for analysis (ie. caprylic acid precipitate, 
plasma pellet, etc.). 
3.2.1 Optimization of Purification of Antibody 
The method described above was initially optimized using gradually increasing amounts 
of ammonium sulfate. In the initial purification procedures, ammonium sulfate was added 
dropwise until a concentration of 23% was achieved. The solution was spun at 10,000x g at 4°C 
for 30 minutes. The supernatant was removed for further purification and the pellet, if any, was 
resuspended in PBS for further analysis. Ammonium sulfate was added to the supernatant at 4°C 
dropwise, while spinning, until a final concentration of 33% was achieved. The solution was spun 
down and separated as before. This process was repeated to achieve a concentration of 43% 
ammonium sulfate. Each product was collected for future analysis to determine which contained 
the largest amount of antibody. Analysis of antibody purity and concentration was performed 
through SDS gels and BCA assays. Binding was assessed through ELISA analysis. 
3.3 SDS Gel Analysis 
Proteins fractions from each step in the purification process were used for SDS-PAGE gel 
analysis [adapted from (59)]. For each lane, 15 µl of protein sample was mixed with 5µl of 
Laemmli 4x sample buffer. Each sample was boiled at 95°C for 5 min, then placed on ice for at 
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least 5 min before loading into gel. Bio-Rad Mini-PROTEAN® TGX™ Precast Gels (4-20%) 
were used in conjunction with the Bio-Rad PowerPac™ Basic Power Supply as well as the 
Precision Plus Protein™ Kaleidoscope™ Prestained Protein Standards as the ladder. Before using, 
the comb and metal strip of the gel was removed, placed in the chamber, and filled to the 2 gel 
(approximately 1L) line with Bio-Rad 1x loading buffer. Each lane was loaded with 7µl of sample 
mix or ladder and allowed to run at 100 V for approximately 60 min. Once the samples had run, 
the gel was removed and stained using Coomassie Blue and Coomassie Blue de-stain (60). 
3.4 Enzyme-linked Immunosorbent Assay (ELISA) Analysis 
Enzyme-linked immunosorbent assays were developed in-house by other members of the 
Reed lab (Le’Kneitah Smith, Elizabeth Stinson, Katherine O’Malley Willett, manuscript in 
preparation). Hyper-immune rabbit plasma was used as a positive control, as established in-house, 
and commercial rabbit low-binding IgG was used as a negative control. In general, high-binding 
96-well plates were coated with heat-killed SchuS4 and allowed to sit overnight at room 
temperature. Coating antigen was removed and replaced with blocking buffer, which was allowed 
to incubate at 37°C for 3 hours. Once the incubation period was over, plates were washed 5 times 
with 0.005% Tween in PBS and stored at 4°C or used immediately for assay. 
Samples were diluted as indicated in PBS-T (1:50 for positive and negative controls), 
which was subsequently diluted by half-logs in duplicate on the plate, with the last row void of 
sample. The plates were then incubated at 37°C for 1 hour, after which they were washed 5 times 
with PBS-T. Once washed, plates were coated with secondary HRP-conjugated antibodies (either 
anti-IgG or anti-IgM), incubated at 37°C for 1 hour and washed again 5 times with PBS-T. After 
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washing, POD Chemiluminescence working solution was added and allowed to sit at room temp 
for 3 min before absorbance was read at 405nm. Analysis was done in the Prism software. 
3.5 Bicinchoninic Acid (BCA) Assays 
Protein concentrations were determined using the Peirce BCA Assay kit and respective 
protocol(61). Briefly, a standard curve was established using known concentrations of BSA in 
PBS. For each standard and sample, 1 part sample/standard was mixed with 20 parts working 
reagent (1:50 of BCA Reagent B and A, respectively) and allowed to incubate at 37°C for 30 min. 
Measurement of protein concentration was performed through spectrophotometric analysis at 562 
nm. Concentrations of samples were determined through Prism software interpolation using the 
standard curve of BSA. Since the assay only determine protein concentrations between 20 and 
2,000 µg/ml, the samples were diluted to 10% or 2% in PBS. 
3.6 Cell Culture 
J774 cells were maintained by serial passage in DMEM supplemented with l-glutamine, 
10% FBS, 1% penicillin-streptomycin, and 1% HEPES buffer. When required for infection, cells 
were washed 3 times with PBS and scraped from tissue culture flasks. The cells were seeded into 
a 12-well plate treated for culture and allowed to incubate for 24 hours before use. 
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3.7 Bacterial Methods and Culture 
Francisella tularensis strain RML (Rocky Mountain Labs) LVS was obtained from 
Catherine Bosio and streaked onto CHA for isolation using a sterile loop. Two days later, 
individual colonies were selected using aseptic technique and used to create a bacterial slurry in 
PBS that was approximately 0.06-0.08 optical density (OD) at a wavelength of 600nm. Five-
hundred microliters of this slurry was added to 29.5 ml of brain heart infusion (BHI) supplemented 
with cysteine and ferric pyrophosphate. The culture was incubated for 16-18 hours at 37°C in a 
shaking incubator set to 200 RPMs. After the culture was allowed to grow, it was harvested with 
a desired OD of approximately 0.1-0.3.  
3.7.1 Determining Aerosol Dose of RML LVS 
Aerosol doses were determined as previously performed by the Reed Lab (62). In general, 
bacteria slurries were aerosolized using a Collison 3-jet nebulizer for 10 minutes. The nebulizer 
was controlled by the AeroMP exposure management system (Biaera Technologies, Hagerstown, 
MD). The AeroMP monitored and controlled all environmental parameters in the exposure 
chamber (relative humidity, temperature, pressure, air input and exhaust). Aerosol sampling was 
done using an all-glass impinger (AGI-4). The nebulizer was operated at 7.5 lpm, 25-30 psig while 
the sampler was operated at 6 lpm, 7-12 psig. For rodent exposures, a whole-body exposure 
chamber (39 l total volume) was used which can hold four metal exposure cages at a time with up 
to 10 mice per exposure cage. Chamber airflow rates were set to 19.5 lpm for both input and 
exhaust, to insure 0.5 air changes/minute in the chamber. For F. tularensis, a humidifcation loop 
was also added to input air to insure relative humidity is at least 65%, based on prior studies in the 
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Reed lab indicating that humidification must be high for good aerosol performance (62). The 
Collison 3-jet nebulizer creates a small-particle aerosol (1-2 µm mass median aerodynamic 
diameter) of bacteria in liquid media that flows at an even rate through the rodent whole-body 
chamber. This allows the animals to move freely inside the mesh cages within the chamber while 
being exposed from both the top and bottom of the chamber in order to maximize efficiency. 
Aerosol doses are calculated after determining the aerosol concentration of the pathogen from the 
AGI sample. Results from previous rodent exposures using the same experimental conditions were 
used to calculate the starting bacteria concentration needed to achieve desired target doses. Inhaled 
or presented dose is calculated as the product of the aerosol concentration, the duration of the 
exposure (10 minutes) and the minute volume of the animal. For mice, Guyton’s formula is 
typically used to calculate minute volume rather than empirical determination; Guyton’s formula 
stipulates that minute volume is a function of the weight of the animal (63). The following formulas 
summarize the calculation of the inhaled dose: 
 
𝑰𝒏𝒉𝒂𝒍𝒆𝒅 𝒅𝒐𝒔𝒆 =  [𝑨𝒆𝒓𝒐𝒔𝒐𝒍] × 𝒆𝒙𝒑𝒐𝒔𝒖𝒓𝒆 𝒕𝒊𝒎𝒆 ×  𝒎𝒊𝒏𝒖𝒕𝒆 𝒗𝒐𝒍𝒖𝒎𝒆 
 
[𝑨𝒆𝒓𝒐𝒔𝒐𝒍] =  
[𝑨𝑮𝑰] × 𝑨𝑮𝑰 𝒗𝒐𝒍𝒖𝒎𝒆
𝑨𝑮𝑰 𝒇𝒍𝒐𝒘 𝒓𝒂𝒕𝒆 × 𝒆𝒙𝒑𝒐𝒔𝒖𝒓𝒆 𝒕𝒊𝒎𝒆
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3.8 LVS Infection of J774 Macrophages 
Infections of J774 cells were performed in BSL2 using sterile techniques. Two days prior 
to infection, LVS (either ATCC strain or RML strain) were streaked onto CHA for isolation. Cells 
were counted with a hemocytometer and seeded at 3 × 105 cells/ml in 12-well plates 24 hours prior 
to infection. On the day of infection, single colonies were selected and vortexed in PBS in order 
to achieve a bacterial slurry with an OD of 0.1-0.3 at 600nm – the linear range of growth for F. 
tularensis. The concentration of bacteria in the slurry was determined using a previously 
established standard equation for F. tularensis (62). This was then diluted with the appropriate 
amount of PBS in order to achieve a multiplicity of infection (MOI) of 100:1 of LVS to J774s. 
Once diluted, 100µl of this slurry or PBS as a control was added to each well in the 12-well plate. 
After the bacteria infected the cells for 2 hours, 2 ml of PBS with 50µg/ml of gentamycin was used 
to wash each well 3 times. After washing, 1 ml of DMEM supplemented with 50 µg/ml 
gentamycin, 10% FBS, and 1% HEPES buffer was added and incubated for another 45 minutes to 
1 hour.  
Following the second incubation, the media in wells for timepoints 24hrs, 48hrs, and 72hrs 
were removed and replaced with DMEM supplemented with 2 µg/ml gentamycin, 10%FBS, and 
1% HEPES. The media in the 0hr timepoint wells were removed and washed 3 times with 2 ml of 
PBS. J774 cells were lysed by incubating 1ml of 0.02% SDS in dH2O at room temp for 
approximately 10 minutes as well as mixing with a pipette 10 times. This solution was serially 
diluted in PBS to 10-6. Each dilution was plated in triplicate using the drop method, and 200 µl of 
the undiluted solution was plated in duplicate on CHA plates and spread using an L-shaped 
spreader. Bacteria were quantified 3-4 days later by counting colony-forming units on plates. 
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3.9 Opsonization of LVS 
Opsonization was assessed as enhanced uptake of F. tularensis by J774 cells after 
incubating bacteria with specific antibody. RML LVS was suspended in PBS to create an initial 
slurry, then diluted down to accomplish a concentration of 3 × 108 CFU/ml as described above. 
This slurry was then incubated with 10% of the antibody solution (500 µg/ml in PBS) at 37°C for 
30 minutes. Antibodies purified from naïve rabbits were used as a control as well as PBS with no 
antibodies added. After incubation, the slurries that were used to infect J774s in opsonization 
infection assays were used directly as the inoculum in the assay described in the previous section. 
Slurries were serially diluted out to 10-8 and plated onto CHA using the drop method. Colonies 
were enumerated approximately 3 days later concentration (CFU/ml) was calculated.  
3.10 Complement Fixation of RML LVS 
Complement fixation assays were performed based on an established protocol (64). 
Slurries of RML LVS were prepared using culturing methods mentioned in section 3.7. 
Approximately 3 × 108 CFU/ml of RML LVS were combined with 10% antibody solutions of 
varying concentrations and 10% rabbit complement (MP Biomedicals™). Antibody solutions from 
both hyperimmune and naïve rabbits were diluted to 1:10, 1:100, and 1:1,000 of the original 500 
µg/ml solution. The naïve rabbit antibody, PBS with complement, and PBS without complement 
were used as negative controls. All slurries of RML LVS with antibody/complement or PBS 
solutions were incubated at 37°C with 5% CO2 for 30 minutes. Bacterial titers were enumerated 
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by serially diluting each slurry and inoculating the dilutions onto CHA plates. The CFUs produced 
were counted 2 days later. 
3.11 Agglutination Tests of RML LVS 
Agglutination tests have historically been used to determine immune response in tularemia 
patients. The agglutination tests in these experiments were based on an established protocol for 
microagglutination testing for tularemia in humans (65, 66). The antigen was prepared by creating 
a slurry of RML LVS that was approximately 1 × 109 CFU/ml. Formalin and Safranin were added 
to the solution for a final concentration of 0.5% and 0.005%, respectively. The antigen stock was 
later serially diluted by 2 until a dilution of 1:128 was achieved, then kept in 4° C until the assay 
was performed. Hyperimmune antibody solution was serially diluted by 2 in PBS in a U-bottom, 
96-well plate starting at 1:10 and stopping at 1:10,240 dilutions. The last column of PBS alone 
served as the negative control. Antigen dilutions were then added to the plate in a 1:1 ratio with 
the antibody solutions (see Figure 28). The plate was incubated at 37°C in 5% CO2 for 24 hours 
before being read initially, but was shortened to 4 hours after the first trial. The optimal antigen 
dilution was determined by the highest dilution of antigen on the plate that produced both positive 
(no button) and negative (button) agglutination results. The final titer was determined as the 
highest antibody dilution that produced agglutination in the optimal antigen row. 
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3.12 LD50 Determination of RML LVS in Aerosol Infection of BALB/c Mice 
Three groups of 6-10-week-old BALB/c mice (n = 5) were exposed via the aerosol route 
to doses of 80, 349, and 1,261 CFUs of RML LVS, respectively. Mice were weighed 24 hours 
before aerosol infection, and weight was measured once per day until mice succumbed to infection 
or recovered. Appearance of mice was also measured using clinical scoring, where 1 = normal, 2 
= reduced grooming, 3 = oily appearance, 4 = hunched, respiratory distress (euthanasia criteria). 
Behavior was measured using clinical score scales as well, with 1 = normal, 2 = subdued, 3 = 
movement when provoked, and 4 = no movement when provoked (euthanasia criteria). Weight 
loss of 5% or less was designated a 1, 2 = up to 10% weight loss, 3 = up to 15% weight loss, and 
4 = up to 20% weight loss. Any animals who lost over 20% of body weight, scored a ‘4’ in either 
behavior or appearance, or had a cumulative score of ‘10’ were promptly euthanized via 
intoxication with carbon dioxide, in accordance with AVMA guidelines.  
Mice were monitored at least twice per day until a total clinical score of 6 was reached, at 
which point animals were examined 3 times per day. Animals were monitored daily until complete 
recovery (total clinical score of 3) or death. After 21 days, the experiment ended, and any 
remaining animals were counted as survivors and euthanized to collect samples for analysis of 
bacterial load and serology. 
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3.13 Antibody Passive Immunization and Subsequent Challenge with Aerosolized RML 
LVS 
Prior to infection, mice were bled from the submandibular vein and blood from each cage 
(n = 5, same group) was pooled together for extraction of plasma using the Microtainer plasma 
separation tubes. Mice were also either ear punched or implanted with IPTT-300 transponders 
(BioMedic Data Systems) for identification. Approximately 24 hours prior to exposure, animals 
were inoculated with 500 µg/ml of purified immunoglobulin suspended in PBS from either 
hyperimmune rabbits or naïve rabbits; PBS alone was also used as a control. In the low-dose 
exposure experiment, mice were given antibodies via intraperitoneal route (200 µl) or intranasal 
(20 µl). In the high-dose challenge, mice were injected only through the i.p. route. On the day of 
infection, 10 mice of the same group were placed into metal cages and exposed to RML LVS 
through aerosol, using a whole-body rodent chamber. A total of 30 mice were challenged per 10-
minute exposure. After infection, animals were observed twice per day. The scoring system and 
euthanasia criteria were the same as described in the previous section.  
After 21 days of infection, all recovered animals were sacrificed and the lungs, liver, and 
spleens of each were harvested as well as blood. Blood was centrifuged at 10,000x g for 2 minutes  
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Figure 4. Timeline schematic of BALB/c experiment. 
 
to separate plasma, which was inactivated for future analysis. The remaining clot in the tube was 
smeared onto CHA plates for qualitative analysis. Harvested organs were frozen over dry ice 
during necropsy before being transferred to a -80°C. Later, the lungs, liver, and spleens were each 
weighed, suspended in 1 ml of PBS, and homogenized. This mixture was plated onto CHA using 
an L-shaped spreader (no dilution) or drop method (10-1 to 10-6 serial dilutions). Three days later, 
all colonies were counted in order to determine bacterial burden in each tissue or plasma. If the 
plates had no Francisella growth, samples were incubated an additional 4 days for a total of 7 
days.  
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4.0 Results 
4.1 Characterization of Immune Plasma from NZW Rabbit Survivors of SCHU S4 ΔaroD 
Prime/Boost Vaccination and SchuS4 Challenge 
4.1.1 SDS Gel Purification 
 
Figure 5. SDS gel analysis of immune plasma purification. 
2) Ladder, 3) commercial IgG, 4) 33% ammonium sulfate precipitate, 5) 43% ammonium sulfate precipitate, 6) 43% 
ammonium sulfate supernatant, 7) caprylic acid precipitate, 9) unfiltered, unpurified hyperimmune plasma. Lanes 1, 
8, and 10 are blank but have not been omitted in order to retain integrity of the gel. 
 
A small portion of each sample produced during the protein purification process was saved 
in order to analyze purity. Figure 5 shows that both the 33% and 43% ammonium sulfate 
concentrations resulted in a large band that was the same size as that seen in the commercially  
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purified rabbit IgG. In contrast, there was no detectable antibody in the supernatant of the 43% 
ammonium sulfate solution. The smaller bands in the 33% and 43% ammonium sulfate pellets 
likely are either impurities or breakdown products but represent a minor portion of the total protein. 
Notably, they are also seen in the commercially prepared IgG except for the lower band at 
approximately 15 kd. 
 
Figure 6. SDS gel to assess purity during each step of the immunoglobulin purification process. 
Lanes were as follows: 2) Ladder, 3) unfiltered plasma, 4) filtered plasma, 5) plasma precipitate, 6) caprylic acid 
precipitate, 7) Immunoglobulin precipitate (43% ammonium sulfate) and 8) 43% ammonium sulfate supernatant. 
Lanes 1, 9, and 10 were blank (not shown). The red box indicates the band of immunoglobulin purified from the 
plasma 
 
Figure 6 shows the SDS gel of samples taken of each product during the optimized 
purification process. Higher concentrations of protein were loaded into this gel than the previous 
gel in Figure 5 in order to better assess the purity of the material at each step in the process. While 
this figure indicates that immunoglobulin is not the only protein in the solution, it does show that 
the band of antibody is highly concentrated. In addition, the purified product has less background 
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protein than the unfiltered plasma, which is seen as a large smear down lane 2. This figure shows 
as a proof-of-concept that the purification process does reduce but does not completely eliminate 
contaminants in the sample.  
4.1.2 ELISA Analysis 
 
Figure 7. ELISA of immune plasma purification products. 
 
Figure 7 shows a logistic regression analysis of ELISA results for IgG from the various 
fractions analyzed. EC50 and slope values for each sample produced during the purification of 
hyperimmune rabbit plasma are shown in Table 10. The EC50 value for the 33% and 43% 
ammonium sulfate precipitate products are relatively the same while the max RLU values are 
slightly different, as noted by the bolded lines and in Table 10. In comparison, the EC50 value of 
the pre-purification plasma is ~20-fold less than either purification products. Thus, both the 33% 
and 43% ammonium sulfate solution purified and concentrated Francisella specific antibodies. In 
this figure, all products are normalized to 500 µg/ml concentration while the positive and negative 
controls remain at their original concentrations. From these results, I determined that the optimal 
purification process was to spin and filter plasma, then add caprylic acid and spin to remove the 
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pellet (Figure 28), and finally to precipitate out the antibodies (denoted IgG pellet later) using 
43% ammonium sulfate solution. 
 
Figure 8. ELISA of Products from Hyperimmune Rabbit Plasma Purification. 
 
Figure 8 shows products from a subsequent purification of hyperimmune rabbit plasma, 
using the optimized process described above. The EC50 and maximum RLU values are shown in 
Table 11. In this process, the plasma was first spun down at 10,000x g before being vacuum 
filtered. This resulted in less loss of product and no clogging of the filter. The bolded dark purple 
line represents the antibody pellet produced, which has an overall higher binding as defined by the 
higher RLU value and higher EC50 dilution than unfiltered plasma from the purification process. 
The purification product from this process was used in future antibody experiments. 
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Figure 9. ELISA of products from naive rabbit plasma. 
 
Figure 9 demonstrates a proof of concept of the final, optimized purification process of 
plasma from a non-immune rabbit. Antibodies purified from this animal’s plasma were not 
Francisella specific, which was expected considering this animal was never immunized or exposed 
to Francisella. The only line shown in this graph is the positive control; the other lines all show 
negative results. The antibodies purified from this rabbit were subsequently used in future 
experiments as a negative control. In future results, they are denoted as non-specific or non-
immune antibodies. 
4.1.3 BCA Assays 
Table 2. Protein Concentrations from Optimizing Plasma Purification. 
Sample 
Interpolated Protein 
Concentration (ug/ml) 
Absorbance at 526 nm 
(10% sample conc.) 
Plasma-control  0.98 
Caprylic acid purified 13753.74821 0.39 
33%(NH
4
)
2
SO
4
 precipitate 2363.080962 0.16 
43%(NH
4
)
2
SO
4
 precipitate 2247.209513 0.16 
43%(NH
4
)
2
SO
4
 supernatant (undiluted) 4.56519784 Too low 
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Figure 10. BCA Standard Curve for Optimization Products. 
 
Table 2 shows the protein concentrations for the samples taken during the optimization of 
the purification process. Interpolated values were calculated using GraphPad software, then 
multiplied by the dilution factor of the samples. The absorbances are recorded from diluted 
samples, except the supernatant, which remained undiluted. The standard curve used to determine 
concentrations is shown in Figure 10. 
 
Table 3. Protein Concentrations from Hyperimmune Rabbit Plasma Purification. 
Sample 
Interpolated Protein 
Concentration (ug/ml) 
Absorbance at 526 nm 
(2% sample conc.) 
unfiltered plasma 70241.78 0.4228 
filtered plasma 66652.65 0.4027 
plasma pellet 12169.93 0.0995 
caprylic acid ppt 5007.782 0.0549 
IgG purified 39877.32 0.2530 
43%(NH4)2SO4 supernatant (undiluted) Too low 0.0146 
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Figure 11. BCA Standard Curve for Hyperimmune Purification Products. 
 
Table 3 shows concentrations of total protein content from each sample during the 
purification of hyperimmune rabbit plasma. These data were used to generate the 500 µg/ml stocks 
of antibody used in future experiments. The standard curve used to interpolate the concentrations 
is shown in Figure 11. 
Table 4. Protein Concentrations from Naive Rabbit Plasma. 
Sample 
Interpolated Protein 
Concentration (ug/ml) 
Absorbance at 526 nm 
(2% sample conc.) 
unfiltered plasma 84260.68571 0.363233333 
filtered plasma 74026.91871 0.3267 
plasma pellet 17665.49514 0.132933333 
IgG purified 43624.41384 0.218166667 
43%(NH4)2SO4 supernatant (undiluted) 534.1016746 0.157766667 
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Figure 12. BCA Standard Curve for Naïve Rabbit Plasma Purification. 
 
Table 4 shows the concentrations of protein content from samples during the purification 
of the naïve rabbit plasma. The interpolated concentration for the purified antibody was used to 
generate the 500 µg/ml stock used as a negative control in future experiments. The standard curve 
used to generate the interpolated concentrations is shown in Figure 12.  
 37 
4.2 Effects of Antibodies on RML LVS 
4.2.1 Opsonization 
 
Figure 13. Incubation of immune antibodies and F. tularensis RML LVS result in lower bacterial titers. 
 
Figure 13 is a compilation of multiple experiments (n = 8) examining the effect of culturing 
antibody preparations with RML LVS. Antibodies (500 µg/ml, immune or non-immune) were 
incubated with RML LVS for 30 minutes at 37°C with 5% CO2. These slurries were then diluted 
out and enumerated on CHA plates. As is seen above, incubating bacteria with immune antibodies 
resulted in significantly lower titers than non-immune (p = 0.0054) and PBS (p = 0.0044) treated 
RML LVS when plated on agar (Brown-Forsythe ANOVA and Dunnett’s multiple comparison 
tests). In contrast, there was no significant difference of RML LVS growth when incubated with 
the PBS control or non-immune antibodies (p = 0.488). 
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Figure 14. Complement-Mediated Killing of RML LVS with Antibodies. 
 
Figure 14 shows the titers of RML LVS when mixed with different dilutions of rabbit 
complement. There was a slightly significant difference overall between titers (Brown-Forsythe 
ANOVA, p = 0.0162). However, there was no significant difference between any combination of 
complement and antibody when compared to either complement alone or PBS controls (Dunnett’s 
Multiple Comparisons Tests). This is surprising because the immune antibody to complement 1:1 
ratio exhibited about a 10-fold reduction in RML LVS titers. This experiment was performed once, 
so future work should also focus on repetition in order to confirm these findings. 
4.2.2 Agglutination Tests 
Table 5. Agglutination Titers of Hyperimmune and Non-Immune Antibodies 
Antibody Optimal Antigen Dilution Agglutination Titer 
Hyperimmune 1:4 1:640 
Naïve 1:8 1:2 
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Table 5 shows the agglutination titers of hyperimmune and naïve purified antibodies from 
rabbits, respectively. It is important to note that these antibodies are standardized to a concentration 
of 500 µg/ml, while many other tests use undiluted sera or plasma. This could explain the relatively 
low agglutination titer of the immune sample compared to literature values (65, 66). The titer of 
the hyperimmune antibodies was 1:640 while the antibody titer for the naïve sample was 1:2. 
Additionally, the optimal antigen concentration was different for each sample. This may be due to 
the difference in balance of bacteria and antibody ratios needed to agglutinate the bacteria inside 
the space of the well. If the antigen concentration is normalized to the hyperimmune antibody 
sample, then the naïve sample would be negative. This experiment was performed twice, so future 
work may want to confirm results by repetition, especially with undiluted purified samples. In 
addition, future work will need to use the same antigen dilution for agglutination tests. 
4.2.3 Infection Assays of J774s 
Infection assays using the J774A.1 cell line often resulted in bacterial titers on all infection 
timepoints except for the initial timepoint (0 hr). The following results are therefore the products 
of the experiments that did manage to produce bacterial titers at all timepoints, albeit very low 
concentrations. More details concerning these experiments and their issues are in the discussion 
section.  
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Figure 15. Comparison of AT C LVS strain and RML LVS straing during infection of J774 cells. 
 
During initial experiments, it was suspected that the ATCC LVS strain used for infection 
assays had lost virulence and ability to infect J774 macrophages. Figure 15 shows the intracellular 
growth of ATCC LVS (purple) and RML LVS (blue) over 72 hours. As can be seen above, the 
RML strain produced colonies during initial infection (0 hr) and sustained intracellular growth up 
to 72 hours. In contrast, the ATCC LVS strain did not produce colonies during the initial infection 
but peaked at 24 hours before decreasing at 48 and 72 hours post infection. Taken together, these 
data indicate that the RML LVS had better initial infection in cells in comparison to the ATCC 
LVS strain. However, ATCC LVS did replicate to higher titers at 24 and 48 hours post-infection 
while the RML LVS had overall less changes in replication from 24 to 72 hours after infection. 
This experiment was performed once. Based on these results, future infection assays and mouse 
experiments used the RML LVS strain instead of the ATCC LVS strain. 
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Figure 16. Effects of opsonization of RML LVS during infection with J774 cells. 
 
The graph above shows an early infection assay using unpurified rabbit immune plasma as 
a positive control and non-immune purified antibodies and PBS as negative controls. In this 
infection, there was increase in the number of intracellular Francisella opsonized with immune 
antibodies either purified or non-purified. Additionally, Francisella incubated with non-immune 
antibodies appeared to stall intracellular growth until 48 hours post-infection.  It is important to 
note that this experiment was one successful trial while many different trials failed. Additional 
repetitions of this experiment would be needed to verify these results. 
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4.3 Passive Protection from Lethal RML LVS Aerosol Infection in BALB/c Mice 
4.3.1 Determining LD50 of RML LVS in Aerosol Infection of BALB/c Mice 
4.3.1.1 Aerosol Dose 
 
Table 6. Aerosol Summary for LD50 Determination 
Target Dose 
(CFU) 
Mice Weight 
(g) 
MV 
(ml) 
[Nebulizer] [AGI] [Aerosol] Spray Factor Inhaled Dose 
10 5 18.1 18.4 1.30E+06 2.60E+03 4.3E+02 3.3E-07 79.7 
100 5 17.5 17.9 1.57E+07 1.17E+04 1.9E+03 1.2E-07 348.8 
1,000 5 17.2 17.7 1.00E+08 4.27E+04 7.1E+03 7.1E-08 1,261.3 
 
The table above summarizes the aerosol challenge of female BALB/c mice in order to 
determine lethal dose. The weights listed above are the average weight of all animals in each group. 
The respective target doses are shown on the left while the actual inhaled doses are shown in the 
last column on the right. 
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4.3.1.2 Survival Curve of BALB/c Mice 
 
Figure 17. Survival of BALB/c mice with varying doses of aerosolized RML LVS. 
 
The graph above shows the survival curve of different target doses in female BALB/c mice. 
Mice infected with the highest dose, approximately 1,000 CFUs, succumbed to infection around 6 
days post-infection. In the group of animals infected with approximately 100 CFUs, about half the 
mice succumbed to infection while the others survived. All mice infected with approximately 10 
CFUs survived infection. 
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4.3.1.3 Clinical Signs of Disease in BALB/c Mice 
 
Figure 18. (A) Weight Loss and (B) Clinical Score of BALB/c Mice Infected with Different Doses of RML 
LVS. 
 
Clinical signs and weight were monitored for 13 days after initial infection of RML LVS. 
Weight loss, shown on the left map, was more severe in mice infected with higher doses of bacteria. 
Additionally, onset of weight loss appeared later after infection in animals with lower doses. 
Clinical scores, shown on the right, were higher for animals with higher doses. Euthanasia criteria 
was reached in animals that succumbed to infection approximately six days after the aerosol. All 
animals that survived were back to baseline weights and scores by 13 days post-infection. Animals 
were sacrificed when the experiment ended after 22 days. 
 
B A 
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4.3.2 Comparison between Treatment Routes 
4.3.2.1 Aerosol Dose 
Table 7: Aerosol Summary for Determining Passive Immunization Route 
 
Mice Weight 
(g) 
MV 
(ml) 
[Nebulizer] [AGI] [Aerosol] Spray Factor Inhaled Dose 
i.p. Tx 30 18.8 19.0 2.37E+08 1.90E+04 3.2E+03 1.3E-08 600.3 
i.n. Tx 30 18.4 18.6 2.37E+08 2.08E+04 3.5E+03 1.5E-08 644.0 
 
 
The table shown above summarizes the dose calculations for the aerosol challenge of 
BALB/c mice. This experiment was designed to determine if there were significant differences in 
the route of antibody administration. The difference in the doses shown above is minimal, leading 
to similar experimental design. 
4.3.2.2 Survival Curve of BALB/c Mice 
 
Figure 19. Survival Curve of BALB/c Mice Passively Immunized Either i.n. or i.p. 
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This graph shows the survival curve of all treatment groups of animals passively 
immunized with PBS, non-immune antibodies, or immune antibodies delivered either intranasally 
or intraperitoneally. In either route, the animals immunized with hyperimmune antibodies survived 
infection while at least 20% of control animals groups succumbed to infection. Interestingly, 
animals inoculated with non-immune antibodies via i.p. route all succumbed to infection while 
animals inoculated with the same non-immune antibodies via i.n. route had 80% survival (Log-
rank test, p < 0.0001). The opposite effect was seen in animals inoculated with the PBS control; 
80% of animals succumbed to infection when inoculated i.n., but only 20% succumbed when 
inoculated via i.p. route. This difference was found to be significantly different (Log-rank test, p 
= 0.0060). 
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4.3.2.3 Weight Loss of BALB/c Mice 
 
Figure 20. Weight Loss of BALB/c Mice Immunized via Different Routes. 
 
Weight loss graphs were separated out based on immunization route. The top graph, (A), 
shows all groups immunized through the intraperitoneal route and the bottom graph, (B), shows 
all groups immunized through the intranasal route. The weight loss of either group corresponds to 
the survival curves in that animals who succumbed to infection lost more weight than animals that 
survived. In the top graph, animals in the non-immune antibody control group lost more weight 
than either the PBS control group or the immune antibody group. In the bottom graph, the PBS 
A 
B 
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control group lost more weight than the non-immune control group or the immune group. This 
trend was seen in all animals of the group (n=10). In both graphs, the most severe weight loss was 
observed around 6-7 days post infection and increased over the next few days until symptoms 
disappeared.  
4.3.2.4 Tissue-Specific Bacterial Burden in BALB/c Mice 
 
Figure 21. Bacterial Titers in the Lungs, Livers, and Spleens of BALB/c Mice Passively Immunized i.p. or i.n. 
 
The differences in bacterial burden among animals are seen in the graph above. There is a 
significant difference between treatment groups (2-way ANOVA, p = 0.0120), but this difference 
only accounts for 8.4% of the total variation seen between animals. Mice inoculated with immune 
antibodies of either route showed slightly less bacterial burden in tissues than any control groups. 
However, this difference was not statistically significant, probably due to the high deviation 
between values (Tukey’s tests). Bacterial titers in the lungs and livers were lower in the surviving 
animals than in animals that succumbed to infection. Bacterial titers in the spleens of the animals 
were not different between survivors and non-survivors. 
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4.3.3 High-Dose Challenges 
The following experimental design was repeated twice since the first trial had an 
overwhelmingly high dose. Since the doses are different by approximately a log, the results could 
not be combined onto one graph.  
4.3.3.1 Aerosol Dose 
Table 8. Aerosol Summary for High-Dose RML LVS Challenge in Mice - Trial 1. 
Mice Weight 
(g) 
MV 
(ml) 
[Nebulizer] [AGI] [Aerosol] Spray Factor Inhaled Dose 
30 18.06 18.40 8.03E+09 3.77E+06 6.28E+05 7.82E-08 1.15E+05 
 
 
Table 9. Aerosol Summary for High-Dose RML LVS Challenge in Mice - Trial 2. 
Mice Weight 
(g) 
MV 
(ml) 
[Nebulizer] [AGI] [Aerosol] Spray Factor Inhaled Dose 
30 17.40 17.90 1.17E+09 8.10E+05 1.4E+05 1.16E-07 2.42E+04 
 
The two tables shown above summarize the aerosol challenges of RML LVS in BALB/c 
mice. Animals were passively immunized approximately 24 hours prior to challenge. In trial 1, the 
calculated inhaled dose is approximately 10-fold higher than in trial 2.  
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4.3.3.2 Survival Curve of BALB/c Mice 
 
Figure 22. Survival Curve of Passively Immunized BALB/c Mice Challenged with RML LVS – Trial 1. 
 
All animals (n=10/group) in challenge trial 1 succumbed to infection around 4-4.5 days 
after the aerosol. There was no significant difference seen between the survival of groups (Log-
rank test, p = 0.059). All animals in the PBS control group succumbed to infection after 4 days, 
while about half of the immune and non-immune groups succumbed. However, by 4.5 days after 
infection, all remaining animals met euthanasia criteria. 
 
Figure 23. Survival Curve of Passively Immunized BALB/c Mice Challenged with RML LVS – Trial 2. 
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BALB/c mice (n=10/group) challenged with a dose 10-fold lower than the animals in trial 
1 demonstrated a different pattern of survival. In this experiment, about half of the animals that 
were administered hyperimmune antibodies had a significant extension of time to death (Logrank 
test for trend, p < 0.0001).  
 
Figure 24. Weisht Weight Loss of BALB/c Mice after Aerosol Challenge, (A) Over Time and (B) on Day 4 
Post Infection. 
4.3.3.3 Weight Loss of BALB/c Mice 
Weight loss of animals challenged with 105 CFU of aerosolized RML LVS exhibited 
profound weight loss leading up to death (Figure 24A). However, on 4 days after infection, 
animals immunized with hyperimmune antibodies showed significantly less weight loss than the 
PBS control group (Tukey’s test, adjusted p = 0.014). There was a slight difference in weight loss 
between immune and non-immune antibodies (Tukey’s test, adjusted p = 0.83). 
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Figure 25. Weight loss of passively immunized BALB/c mice after high-dose aerosol challenge of RMS LVS. 
 
Mice challenged with a dose 10-fold less than before still lost a large amount of weight 
after 4 days (Figure 25). Unlike the first trial, animals given hyperimmune antibodies lost 
significantly less weight than PBS on days 1 (p = 0.042), 3 (p = 0.024), 4 (p = 0.0076), and 5 (p 
= 0.0076) after challenge. Hyperimmune animals also lost significantly less weight than non-
immune antibody groups on days 4 (p = 0.00073) and 5 (p = 0.000005)  after challenge. Taken 
together, these data indicate that there were larger differences seen when comparing the 
hyperimmune antibody treated animals with PBS contols compared to the non-immune antibody 
controls. This could be due to non-immune antibodies playing a role in mitigating disease in mice 
compared to the PBS control, although this difference was not significant. All reported statistics 
were t-tests performed in GraphPad. 
 
A B 
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4.3.3.4 Tissue-Specific Bacterial Burden in BALB/c Mice 
 
 
Figure 26. Bacterial burden in immunized BALB/c mice challenged with high-dose RML LVS. 
 
Bacterial burdens of animals challenged with the highest dose of RML LVS are shown in 
Figure 26. The bacteria in the lungs of the PBS control group were unable to be enumerated; 
bacteria titers were not diluted enough, and samples were discarded. Bacterial burden between 
immune and non-immune groups was not significantly different in any of the tissues. However, 
both the non-immune and immune animals had significantly less bacterial burden than the PBS 
group in the liver and spleen (t-test). This trend would likely also be seen in the lungs, since the 
bacterial burden was too high to be counted. * p < 0.05, ** p < 0.001 
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5.0 Discussion 
5.1 Plasma Purification 
The novelty of this work is that I purified antibodies from plasma in order to create a protein 
mix that was relatively purer than plasma alone and contained a known amount of protein in the 
solution. There have been numerous studies examining the effects of injecting serum or plasma 
into different animals in order to try to confer protection against tularemia, with mixed results (see 
Table 1). Other studies examined monoclonal antibodies, but no one has yet to look at a purified 
polyclonal antibody solution that we have examined here. It was my hope that the purification 
method I used would be suitable for concentration of antibody and removal of other proteins, 
generating a material useful for evaluating the role of antibody in protection against tularemia. 
Purification and concentration of antibody has not been previously attempted in studies evaluating 
the role of antibody in protection against tularemia (31), (see Table 1). Using a combination of 
standard antibody biochemistry protocols (57, 58), I was able to achieve an affordable method to 
crudely purify antibody out of plasma for use in preliminary research. If this therapeutic was to be 
further tested for use in humans, a more refined purification method would be desirable (such as a 
column).  
My experiments indicate that 43% ammonium sulfate solution was optimal for purifying 
and precipitating out rabbit antibodies. When the purification products were normalized by total 
protein concentration (500 µg/ml), large differences were seen in the EC50 curves for IgG. Purified 
rabbit antibodies resulting from the 33% or 43% saturated ammonium sulfate had an overall higher 
avidity than the other products of the purification process. It should be noted that each product of 
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the purification process had remnants of antibody in the solution, as indicated by the EC50 titration 
curves. This means that during each step in our process, there was some loss of antibody. This is 
consistent with reports in the literature for antibody purification and concentration using these 
methods. In future studies, this process could be refined further to minimize this loss, such as using 
affinity columns 
5.2 In vitro Effects of Antibody on F. tularensis RML LVS 
Phagocytosis is a key event during the Francisella life cycle in a mammalian host (17). 
Studies examining opsonization of Francisella with serum found that the FcγR and C3R may 
dictate the route of the intracellular bacteria after uptake (38). While not fully understood, it is 
thought that opsonization by serum or complement redirect Francisella bacteria to pathways that 
may initially result in bacterial killing. Opsonization experiments in this work focused on changes 
in bacterial growth extracellularly through changes in titers and intracellularly through infection 
assays. Mixing LVS bacteria with antibodies resulted in significantly reduced titers of bacteria 
when grown on CHA plates, as is shown in Figure 13. This is likely due to the clustering of 
bacteria through agglutination, as seen in Table 5. It could also be due to direct killing of the 
bacteria by antibodies, although this was not tested. Many groups have found that complement 
does not cause bacterial killing in F. tularensis (36, 38, 67). Complement protein C3 mediates 
bacterial uptake into phagocytes, but the cascade does not continue to form the attack complex 
(67). This finding was further confirmed based on the results of Figure 14, which shows that there 
was no difference between the bacterial titers of RML LVS when complement was added, even 
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though the 1:1 ratio had approximately a 10-fold decrease in bacterial titers. This experiment was 
performed once, so in future work these results should be confirmed through repetition.  
Intracellular growth was extremely difficult to characterize in J774 cells, as is discussed in 
more detail later in this section. The one infection assay that did result in growth at all time points 
is shown in Figure 16. This experiment used a high concentration of purified antibody from both 
naïve rabbits and hyperimmune rabbits. Additionally, unpurified regular immune plasma was used 
as a positive control. Based on the results of this assay, there was an increase in initial uptake of 
bacteria by J774s as seen in the increase of titer at 0 hours post-infection. At later timepoints, 
though, immune plasma and antibodies caused observed death of the J774s (not shown) and 
reduced titers of LVS on CHA plates.  
Infection assays using J774A.1 macrophage-like cells were largely unsuccessful despite 
numerous efforts. The main issue was detecting bacteria inside cells shortly after initial infection, 
approximately 3-4 hours after LVS slurries were first added to cell monolayers. This timing was 
dependent on pipetting skills during the wash steps of the assay, which was time-consuming and 
dependent on the number of plates used in the assay. Undetectable levels of LVS resided inside 
the macrophages, which were later detected by higher titers at later time points. This was 
particularly confusing because this assay has worked for other groups (68-70) and previous 
members of the Reed lab. During initial experiments, it was thought that the original ATCC LVS 
stock we used was becoming damaged in some way during the freeze-thaw process. Thus, we 
decided to create a stock of RML LVS sent to the Reed lab from colleagues at Rocky Mountain 
Labs. Figure 15 shows a successful infection assay comparing the intracellular growth between 
the RML LVS biovar and the ATCC LVS biovar. Based on this assay, it appeared that RML LVS 
was more successful at infecting J774 cells than the ATCC LVS, as indicated by the relative titers 
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at 0 hours post-infection. During the 24-hour timepoint, RML LVS did not produce as high of a 
titer as the ATCC LVS. However, the ATCC LVS biovar peaked at 24-hours post-infection before 
dramatically decreasing at 48- and 72-hours post-infection. These data indicate that while the RML 
LVS did not grow to as high of a titer as the ATCC LVS, it did produce a more sustained infection 
in the macrophage-like cells. This is important because it may relate to the pathogenesis of RML 
LVS seen in mice during later experiments.  
5.3 Passive Immunization of BALB/c Mice Against Aerosolized RML LVS 
The mouse experiments in this work were performed using the RML LVS biovar of 
Francisella tularensis subsp. holarctica. This strain was chosen because it has been shown to be 
more virulent in mice than the ATCC LVS (4), leading to a more stringent challenge. Additionally, 
RML LVS has not yet been used in aerosol infections of BALB/c mice before, so we were also 
interested to see the differences between this biovar and the ATCC biovar. Mice without any 
treatment succumbed to infection about 4-5 days after infection, which was similar to previous 
work in the Reed lab (62). However, the LD50 and LD99 of RML LVS was approximately 10-
fold lower than the ATCC biovar used previously. It should be taken into consideration that LVS 
of either biovar is not as translatable as virulent type A or B strains and that mice are not as 
translatable to humans as other models. Mice are more susceptible to Francisella infections, and 
while an infection with LVS may not cause disease in humans, it can be a lethal infection in mice. 
Thus, while antibodies alone did not protect mice from lethal infections, these experiments should 
be repeated in the rabbit model. In other studies (see Table 1), antibodies alone have not protected 
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mice from infection with the fully virulent Schu S4 strain. On the other hand, rats have been 
successfully passively immunized against Schu S4 (71). 
The route of administration of immune antibodies did not appear to make a difference in 
survival or bacterial burden in BALB/c mice (Figures 19-21). It was surprising that the i.p. non-
immune antibody group succumbed to infection while the i.n. non-immune antibody group had 
80% survival. This may be due to the biological route of infection, since antibodies may have 
remained localized in the respiratory tract on the day of infection. In these areas of the body, the 
non-immune antibodies may have had some non-specific binding to F. tularensis, allowing the 
animals to control infection better than the PBS control. However, PBS administered i.p. resulted 
in 80% survival, while PBS administered i.n. resulted in 20% survival. It is unlikely that the 
treatment groups were switched at any time during the experiment due to human error. While 
unlikely, maybe the i.p. PBS provided extra fluids to the animals before infection, serving as some 
sort of pre-exposure supportive care while PBS delivered i.n. deposited excess fluid in the lungs, 
becoming a co-morbidity in these animals. It is more likely though that the low challenge dose had 
some unexpected effects on the differences in survival, making it impossible to interpret these 
results. 
Animals treated with immune Ab and challenged with 2.42 × 105 CFU of RML LVS had a 
significant extension of time to death by about 6 days. When animals were challenged with a 
bacterial dose 10-fold higher, there was no significant extension in time to death, although animals 
in the immune group did lose significantly less weight than the PBS control group on day of 
euthanasia. Bacterial burden of animals in the PBS control group were significantly higher in the 
spleens and livers compared to the antibody groups. These data suggest that a single bolus of 
antibody may control the infection for a short time but cannot offer full protection. This supports 
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the idea that hyperimmune antibodies were able to prevent F. tularensis from disseminating from 
the lungs of at least a few mice. Additionally, similar results were seen in the bacterial burdens of 
animals challenged with sub-lethal doses, although these results were not significant.  
Overall, the data in these experiments indicate that antibodies do play a role in protection 
against tularemia, as seen by the differences in weight loss, bacterial burden, and time to death. 
However, antibodies in a single inoculation were not sufficient to fully protect BALB/c mice 
against aerosolized F. tularensis infection at high challenge doses. Antibody seems to function by 
binding to F. tularensis in the body, increasing uptake in macrophages. Studies by other groups 
indicate that this uptake is modified by the opsonizing condition of the bacteria in vitro (38) and 
in vivo (36). This process and subsequent bacterial killing is not dependent on complement (36), 
although future work should confirm these results since the experiment was performed once in this 
work. 
5.4 Importance 
Currently, there is no licensed vaccine to protect against tularemia. Since this disease is 
rare, there are ethical and resource barriers in vaccine development. It would be logistically 
difficult to conduct trials of any vaccines in humans, so the main route of licensure many 
researchers go by is using the FDA Animal Rule. According to this rule, the exact mechanisms of 
protection elicited by a candidate vaccine must be characterized in order to further proceed in the 
licensure process (28). Our lab has previously examined multiple live vaccine candidates in the 
rabbit model, which offers a more human-like clinical presentation of disease (8). This work 
provides further insight into the debated role of antibody in vaccine-elicited protection from 
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virulent F. tularensis strain Schu S4. Taken together, we have shown that antibodies produced in 
these hyperimmune rabbits had high avidity to Schu S4 bacteria, resulting in higher binding and a 
reduction in bacterial titers when grown on CHA plates. These antibodies did not provide complete 
protection in the mouse model, indicating that while antibodies may be important, they are not a 
sole mechanism of protection. However, future work should confirm this by assessing whether 
multiple injections of antibody over time might confer protection in mice. Numerous other studies 
indicate that cellular immunity is important for protection against intracellular bacteria such as 
Francisella, while antibodies have been thought to play no role at all. However, this work supports 
the findings that while antibodies may not be protective alone, they do play a role in the immune 
response to Francisella species. 
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Appendix Supplemental Tables and Figures 
 
Figure 27. Infection Assay Schematic 
 
Figure 28. Purification of Antibody Schematic. 
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Table 10. ELISA Values of Optimization of Plasma Purification. 
 Positive 
Control 
Negative 
Control 
plasma 
Caprylic 
Acid ppt 
33% 
(NH
4
)
2
SO
4 
ppt 
43%(NH
4
)
2
SO
4 
ppt 
43% (NH
4
)
2
SO
4
 
Supernatent 
Max 
RLUs 
8740000 167000 7080000 6890000 6620000 6280000 3750000 
EC50 10250 67.24 580.3 1070 10538 13554 ~ 544.8 
Log 
EC50 
4.011 1.828 2.764 3.029 4.023 4.132 ~ 2.736 
r2 value 0.9591 0.8313 0.9906 0.9829 0.9129 0.9466 0.8693 
 
Table 11. ELISA Values of Hyperimmune Plasma Purification Products. 
 
Positive 
Control 
Negative 
Control 
Unfiltered 
Plasma 
Filtered 
Plasma 
Plasma 
pellet 
Caprylic 
Acid ppt 
IgG 
Pellet 
43% (NH4)2SO4 
Supernatent 
Max 
RLUs 8740000 167000 4700000 15000 6510000 691000 6180000 3370000 
EC50 
10250 67.24 2652 239.7 611.1 12969 6011 4312 
Log 
EC50 4.011 1.828 3.424 2.380 2.786 4.113 3.779 3.635 
r2 
value 0.9591 0.8313 0.9108 0.1539 0.9917 0.4326 0.9329 0.7965 
 
Table 12. ELISA Values of Naïve Rabbit Plasma Purification Products. 
 
Positive 
Control 
Negative 
Control 
Unfiltered 
Plasma 
Filtered 
Plasma 
Plasma 
pellet 
IgG Pellet 43% (NH4)2SO4 
Supernatent 
Max 
RLUs 8740000 167000 203000 229000 175000 192000 102000 
EC50 
10250 67.24 7.091 ~ 17.36 ~ 102.0 ~ 33.88 ~ 510.1 
Log 
EC50 4.011 1.828 0.8507 ~ 1.240 ~ 2.009 ~ 1.530 ~ 2.708 
r2 value 
0.9591 0.8313 ** 0.9950 0.9732 0.8775 0.6063 
** - GraphPad software unable to calculate r2 value 
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Figure 29. Agglutination Schematic Showing Antibody and Antigen Dilutions. 
 
Figure 30. Survival of i.n. Treated Mice Only. 
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Figure 31. Survival of i.p. Treated Mice Only. 
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